OMERS ADMINISTRATION Corp Grows Position in Zoetis Inc. $ZTS

OMERS ADMINISTRATION Corp lifted its position in Zoetis Inc. (NYSE:ZTS) by 79.5% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 29,535 shares of the company’s stock after purchasing an additional 13,084 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Zoetis were worth $3,491,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ZTS. Vanguard Group Inc. raised its holdings in Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after buying an additional 5,474,210 shares during the last quarter. J. Stern & Co. LLP grew its holdings in Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares during the last quarter. State Street Corp grew its holdings in Zoetis by 0.8% in the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after acquiring an additional 149,382 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Zoetis by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after acquiring an additional 189,235 shares during the period. Finally, Norges Bank purchased a new position in shares of Zoetis in the fourth quarter valued at about $734,425,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Zoetis

In other news, Director Frank A. Damelio bought 6,650 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul Bisaro bought 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders bought 11,650 shares of company stock valued at $886,384. Corporate insiders own 0.22% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on ZTS shares. Citigroup dropped their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. TD Cowen reduced their price target on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, June 30th. Barclays lowered their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Morgan Stanley dropped their price objective on Zoetis from $115.00 to $99.00 and set an “overweight” rating for the company in a report on Wednesday, July 22nd. Finally, UBS Group reduced their target price on Zoetis from $99.00 to $85.00 and set a “neutral” rating on the stock in a research note on Monday. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus target price of $118.33.

Zoetis Trading Up 2.1%

NYSE:ZTS opened at $76.91 on Tuesday. The company has a 50-day moving average price of $77.27 and a 200-day moving average price of $103.71. The stock has a market cap of $32.24 billion, a price-to-earnings ratio of 12.75, a P/E/G ratio of 1.18 and a beta of 0.75. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 12 month low of $71.47 and a 12 month high of $160.48.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter in the prior year, the firm earned $1.48 EPS. Zoetis’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts predict that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. Zoetis’s dividend payout ratio is 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.